Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Extension Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Next Previous
Trial Profile

An Open Label Extension Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Cushing syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Corcept Therapeutics

    • Most Recent Events

    • 14 May 2015 According to a Corcept Therapeutics media release, data from this study was presented in the posters at the 24th annual American Association of Clinical Endocrinologists in May 2015.
    • 05 Mar 2015 According to a Corcept Therapeutics media release, data from this study were presented at the 97th annual Endocrine Society Meeting (ENDO 2015).
    • 01 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top